Allspring Global Investments
KROS icon

Allspring Global Investments’s Keros Therapeutics KROS Stock Holding History

Allspring Global Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-124
Closed -$3.95K – 2492
2023
Q3 		$3.95K Sell
124
-562
-82% -$21K ﹤0.01% 2685
2023
Q2 		$27.6K Sell
686
-735
-52% -$32.2K ﹤0.01% 2415
2023
Q1 		$60.7K Sell
1,421
-682
-32% -$34.4K ﹤0.01% 2224
2022
Q4 		$101K Sell
2,103
-46
-2% -$2.15K ﹤0.01% 2080
2022
Q3 		$80K Buy
+2,149
New +$74.5K ﹤0.01% 2166

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments's KROS Position: Q4 2023 in Review

Allspring Global Investments sold out of Keros Therapeutics (KROS) in Q4 2023, closing a stake of 124 shares — an estimated $3.95K sold.

Allspring Global Investments first reported a position in KROS in Q3 2022 and held it in 5 quarters. The position peaked at $101K in Q4 2022. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

  • Allspring Global Investments reported no remaining Keros Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 124 Keros Therapeutics shares in Q4 2023, an estimated $3.95K.
  • Allspring Global Investments first reported a position in Keros Therapeutics in Q3 2022 and held it in 5 quarters.
  • Allspring Global Investments's Keros Therapeutics position peaked at $101K in Q4 2022.
  • 121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.